1. Pink Sheet
  2. >>Vaccines

Vaxneuvance, Prevnar 20 Earn CDC Cmte Nod For Age- And Risk-Based Use; Broader Shingrix Use Supported

 
• By Bridget Silverman

ACIP votes unanimously to recommend Merck and Pfizer’s pneumococcal vaccines in elderly and immunocompromised adults; GSK’s herpes zoster vaccine also gets unanimous nod for immunocompromised adults.

Lonely White Sailboat (Alamy)
VACCINES FROM PFIZER, MERCK AND GSK SAILED THROUGH THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES. • Source: Alamy

New pneumococcal conjugate vaccines from Pfizer Inc. and Merck & Co., Inc. and use of GlaxoSmithKline plc’s herpes zoster vaccine Shingrix in immunocompromised adults sailed through the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices on 20 October, resulting in three unanimous votes to recommend use of vaccines.

ACIP has been holding to a swift pace of non-COVID-19 vaccine assessments despite the tremendously increased workload before the committee...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 
• By Eliza Slawther

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

Pink Sheet Podcast: US FDA’s Private Pharma CEO Tour, HHS Changes COVID-19 Vaccine Advice

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.

US FDA Meeting Drought Ends … With A Vengeance

 
• By Michael McCaughan

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.

More from Pink Sheet

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 
• By Neena Brizmohun

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

EU Pharma Reform: Council Proposal A ‘Step In The Right Direction’ But ‘More Work To Be Done’

 
• By Eliza Slawther

Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.